CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies

CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies

Item
http://www.wikidata.org/entity/Q37184796
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment.Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies.New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.Interactions Between Therapeutic Proteins and Small Molecules: The Shared Role of Perpetrators and Victims.Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates.Brentuximab vedotin: clinical updates and practical guidance.CYP Suppression in Human Hepatocytes by Monomethyl Auristatin E, the Payload in Brentuximab Vedotin (Adcetris®), is Associated with Microtubule Disruption.Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
P2860

CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies

Item
http://www.wikidata.org/entity/Q37184796
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CYP3A-mediated drug-drug inter ...... itive hematologic malignancies
@en
CYP3A-mediated drug-drug inter ...... tive hematologic malignancies.
@nl
type
label
CYP3A-mediated drug-drug inter ...... itive hematologic malignancies
@en
CYP3A-mediated drug-drug inter ...... tive hematologic malignancies.
@nl
prefLabel
CYP3A-mediated drug-drug inter ...... itive hematologic malignancies
@en
CYP3A-mediated drug-drug inter ...... tive hematologic malignancies.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P932
P356
P1433
P1476
CYP3A-mediated drug-drug inter ...... itive hematologic malignancies
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P932